News
MAZE
34.91
+2.11%
0.72
Weekly Report: what happened at MAZE last week (1102-1106)?
Weekly Report · 1d ago
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
NASDAQ · 5d ago
Weekly Report: what happened at MAZE last week (1026-1030)?
Weekly Report · 11/02 09:21
Leerink Partners Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)
TipRanks · 10/29 12:19
Maze Therapeutics: Buy Rating Backed by MZE829 Upside in APOL1-Mediated Kidney Disease Ahead of HORIZON Phase 2 Readout
TipRanks · 10/27 00:25
Analyst Reiterates Buy on Maze Therapeutics as Phase 2 HORIZON Data for MZE829 Support APOL1 Strategy; Price Target Maintained at $110
TipRanks · 10/26 10:55
Weekly Report: what happened at MAZE last week (1019-1023)?
Weekly Report · 10/26 09:21
Maze Therapeutics: Buy Rating Reaffirmed on APOL1 Program Momentum and AMKD Market Potential; $50 Price Target Maintained
TipRanks · 10/26 00:25
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Maze Therapeutics, Inc. (MAZE) and Abbott Laboratories (ABT)
TipRanks · 10/21 14:50
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
NASDAQ · 10/19 15:00
Intel upgraded, PayPal downgraded: Wall Street’s top analyst calls
TipRanks · 10/19 13:40
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
NASDAQ · 10/19 12:55
Maze Therapeutics Price Target Announced at $75.00/Share by Canaccord Genuity
Dow Jones · 10/19 12:26
Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75
Benzinga · 10/19 12:16
Maze Therapeutics initiated with a Buy at Canaccord
TipRanks · 10/19 09:41
Weekly Report: what happened at MAZE last week (1012-1016)?
Weekly Report · 10/19 09:21
Maze Therapeutics adjusts equity via warrant exchange
TipRanks · 10/16 20:34
Maze Therapeutics, Inc. (MAZE) Gets a Buy from Wells Fargo
TipRanks · 10/15 11:58
Weekly Report: what happened at MAZE last week (1005-1009)?
Weekly Report · 10/12 09:22
Analysts Are Bullish on These Healthcare Stocks: Alkermes (ALKS), MoonLake Immunotherapeutics (MLTX)
TipRanks · 10/05 11:00
More
Webull provides a variety of real-time MAZE stock news. You can receive the latest news about Maze Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.